Abstract
Dipeptidyl peptidase-4 (DPP-4) inhibitors have been the most widely used for type 2 diabetes (T2D); available worldwide since 2006. DPP-4 inhibitors exert their effects by inhibiting dipeptidyl pep...

This publication has 54 references indexed in Scilit: